Status:
UNKNOWN
Neurofilament Light Chain as Diagnostic and Prognostic Marker in naïve Multiple Sclerosis Patients
Lead Sponsor:
Assiut University
Collaborating Sponsors:
Al-Azhar University
Conditions:
Role of Neurofilment in Diagnosis of Multiple Sclerosis
Eligibility:
All Genders
16-60 years
Brief Summary
Neurofilament protein detected in the serum appears to be a good marker for the extent of active neurodegeneration. Chitinase may also be a good marker reflecting the degree of astrocyte activation, o...
Detailed Description
Many immunological studies have been performed with the aim to identify MS specific biomarkers and disease mechanisms and to find markers able to predict clinical disease course and outcome (Housley e...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All patients newly diagnosed MS according to the 2017-McDonalds criteria.
- Exclusion criteria:
- patients who are already diagnosed MS and under DMTs treatment
- Presence of other disorder or on medications that may affect the neurological or cognitive disorders.
- Patients failed to commit to the follow up visits and regular MRI scans
- Patients refused to sign the written informed consent
Exclusion
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT06197841
Start Date
December 1 2023
End Date
December 1 2024
Last Update
January 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmed El menshawy
Asyut, Egypt